Latest News- Hospital Infection Therapeutics Market: Antibiotics drugs is expected to lead the Drug Class segment during 2025-2029

The Hospital Infection Therapeutics Market is being driven by Increase in incidence and prevalence of respiratory disorders

The Hospital Infection Therapeutics Market is expected to grow at a CAGR of 5.5% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 3786.3 million. The global rise in chronic diseases is driving an increase in hospital patient visits, leading to a corresponding surge in the prevalence of healthcare-associated infections (HAIs). Central venous catheters, a common medical device used in hospitals, are a significant contributor to HAIs. It is projected that their usage will expand by 8% by 2025, heightening the risk of hospital infection diseases. Hospitals serve as a significant source of infections, resulting in increased morbidity and mortality among hospitalized patients. Intensive Care Units (ICUs), in particular, are susceptible to infections due to the high number of invasive, therapeutic, and diagnostic procedures performed there. Sepsis, a severe complication of hospital infection diseases, poses a significant threat to patient health. 

Get more information on Hospital Infection Therapeutics Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Drug Class
  • Antibiotics drugs
  • Antifungal drugs
  • Antiviral drugs
• Type
  • Respiratory tract infections
  • Surgical site infections
  • Bloodstream infections
  • Gastrointestinal infections
  • Urinary tract infections
• End-user
  • Hospitals
  • Ambulatory surgical centers
  • Specialty clinics
  • Long-term care facilities
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Asia
    • China
    • India
    • Japan
    • South Korea
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increase in incidence and prevalence of respiratory disorders
• Growing geriatric population
• Special drug designations

However, the market also witnesses some limitations, which are as follows:

• Stringent regulations
• High cost of therapeutics
• Development of antibacterial resistance

Benefits of Buying Global Hospital Infection Therapeutics Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Hospital Infection Therapeutics Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Hospital Infection Therapeutics Market focuses on combating antibiotic-resistant bacteria such as Vancomycin-Resistant Enterococci (VRE), Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae (CRE), Acinetobacter Baumannii, and Pseudomonas Aeruginosa. Solutions include biofilm disruptors, antimicrobial coatings, and antimicrobial surfaces. Surveillance systems, molecular diagnostics, rapid diagnostics, and point-of-care testing are essential for early detection. Whole genome sequencing, data analytics, AI, and machine learning aid in understanding and addressing antibiotic resistance. Precision and personalized medicine, stewardship programs, patient education, and healthcare worker education promote effective treatment. Infection control audits and quality improvement initiatives ensure patient satisfaction and positive healthcare outcomes.

Market Research Overview

The global Hospital Infection Therapeutics Market encompasses businesses involved in the research and development (R&D) or manufacturing of antimicrobial agents, including antibacterial drugs, antiviral drugs, and anti-fungal drugs. According to Technavio, the size of the global pharmaceuticals market is determined by the consolidated revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of this market include the increasing aging population, with predictions that by 2050, approximately one-quarter of the US and European populations will be over 60 years old, leading to a higher prevalence of healthcare-associated infections (HAIs) and hospital-acquired infections (HAIs). These infections necessitate the use of antimicrobial agents and other therapeutics, thereby fueling market expansion.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/